6 min read

When the Investment Thesis Changes

What happens when a good healthcare company no longer fits the business plan or the market?

Written by

Dan Neuwirth

Managing Partner

·

Realize Health Ventures

Back to all Insights

←

There's an uncomfortable moment in the life of many healthcare companies when the founders realize two things can be true at once: The company is making progress. And the investment thesis that attracted investors is no longer playing out as planned.

Maybe commercial traction is taking longer than expected. Maybe reimbursement is proving more complicated than the pitch deck suggested. Maybe the product works beautifully, but the people who benefit from it aren't the people willing to pay for it.

Or perhaps the company is doing just fine. It's the capital markets that have moved on.

A good company and a good investment aren't always the same thing. And what constitutes a good investment can change remarkably quickly.

When the Money Moves On

Institutional investors have a remarkable ability to arrive at the same conclusion at roughly the same time.

Not long ago, nearly every healthcare technology company was expected to have a compelling digital health story. More recently, the conversation has been dominated by artificial intelligence. If AI is central to your business, you're in the right conversation. If it isn't, you may find yourself explaining why your perfectly viable healthcare company deserves attention in a room looking for something else.

Investors follow opportunities they believe will generate the greatest returns. But the resulting concentration of capital creates challenges for companies that don't fit the narrative of the day.

The numbers tell a different story than the headlines. In the first half of 2026, just over 8% of U.S. digital health financing rounds captured 45% of the capital invested, according to Rock Health. By the third quarter, CB Insights reported that mega-rounds accounted for 56% of global digital health funding—the third consecutive quarter above 50%.



And investors weren't simply writing bigger checks. They were favoring particular opportunities. According to HSBC Innovation Banking, provider operations attracted $3.3 billion in HealthTech investment during the first half of 2026, followed by alternative care at $2.1 billion. Healthcare navigation attracted $900 million, while clinical trials received $400 million.



AI has become so pervasive that distinguishing AI-enabled companies from everyone else is increasingly meaningless. Which doesn't mean investors have stopped looking for an AI story. Quite the opposite. It's becoming the price of admission.

There's plenty of capital available. Just not necessarily for your company.

For founders, the problem is that investor enthusiasm can change much faster than a healthcare business can adapt. Clinical validation, reimbursement, provider adoption, and enterprise sales cycles operate on their own timelines. Unfortunately, those timelines rarely consult the venture capital market.

A company may still have considerable potential, but the capital required to realize it may no longer be available on the terms—or within the timeframe—originally anticipated.

Which raises three questions founders and CEOs eventually have to answer.

1. Raise More Capital—or Change the Plan?

When a company falls behind its original trajectory, the default response is often to raise more money.

After all, that's the plan. Raise capital, reach milestones, demonstrate growth, raise more capital. Repeat until the company becomes profitable, gets acquired, or reaches some other hopefully impressive outcome.

It's an effective strategy. Until it isn't.

More capital may be exactly what a company needs. A delayed regulatory approval, a longer-than-expected sales cycle, or a promising product approaching commercial scale may justify another investment.

But there's an important difference between financing a business through an inflection point and financing the hope that an inflection point will eventually appear.

Capital should fund progress, not substitute for it.

Does the business need more time, or a different strategy? Can it reach meaningful milestones with less capital? Would narrowing the commercial focus produce better results than pursuing the full market opportunity?

These are uncomfortable questions when the answers imply a different company than the one investors originally funded.

Sometimes the smartest growth strategy is to stop chasing growth for a while.

2. Keep Building or Find Someone Better Positioned to Build It?

Founders typically view an acquisition as the reward for building a successful company.

First build the business. Then scale it. Then sell it.

It's a logical sequence, but not necessarily the most valuable one.

A healthcare company may have developed excellent technology, meaningful clinical evidence, established customer relationships, and valuable intellectual property. Yet it may lack the capital, distribution, reimbursement infrastructure, or commercial resources needed to turn those assets into a substantial independent business.

A strategic buyer may already have everything the company is spending years and millions of dollars trying to build.

Sometimes the highest value of a business is realized by someone other than the company that created it.

That doesn't mean every financing challenge should trigger a sale process. But it does suggest founders should evaluate strategic alternatives earlier than they often do.

Acquisitions, partnerships, licensing arrangements, and other strategic combinations may provide pathways to realizing value that independent growth cannot.

The relevant comparison isn't between selling today and achieving the founder's original vision five years from now. It's between the realistic, risk-adjusted value of remaining independent and the value available through a strategic alternative.

And timing matters.

A company exploring strategic alternatives with two years of liquidity has options. A company exploring those same alternatives with two months of liquidity has a very different conversation.

3. What Happens When Your Investors Don't Agree?

Founders and investors begin with an apparently shared objective: Build a valuable company and generate attractive returns.

The complications emerge when they disagree about how to get there or how long they're willing to wait.

A founder may see another 18 months of development as the final stretch before commercial success. An investor may see another 18 months of capital requirements, execution risk, and delayed liquidity.

Both perspectives can be entirely reasonable.

Then there's the investor who believes in the company, likes the management team, and wants everyone to succeed but isn't putting in any more money.

That presents a particularly interesting problem when the company needs existing investor support to attract new capital.

An investor can remain enthusiastic about a company without remaining enthusiastic about financing it.

Different investors bring different incentives. Some have available capital and long investment horizons. Others face portfolio pressures, fund maturity, or liquidity requirements. Preferred shareholders may view a financing or acquisition differently from founders and common shareholders.

And existing investors who won't participate in new financing may still have the influence or contractual rights to complicate it.

The CEO's challenge is to bring investors into a candid reassessment of the business, not defend a forecast everyone quietly knows has become unrealistic.

That means presenting credible alternatives, addressing their economics, and building alignment around a path forward. Ideally before a financing negotiation or sale process forces the issue.

The Goal Isn't to Preserve the Plan

Healthcare companies operate in an environment where development timelines are uncertain, business models evolve, and investor appetite can change almost overnight.

None of this necessarily means something has gone wrong.

But the strategy that made sense at the last financing may no longer be the one that creates the most value today.

Founders have an understandable attachment to the vision that inspired them. Investors have an equally understandable interest in realizing a return.

The CEO's responsibility is to reconcile those interests with the realities of the business.

The objective isn't to prove that the original investment thesis was right. It's to realize the greatest possible value from the company as it exists today.

And preferably to make that decision while there's still a choice.


Sources

  • Rock Health, H1 2026 U.S. Digital Health Funding Overview.

  • CB Insights, State of Digital Health Q3'26, October 15, 2026.

  • HSBC Innovation Banking, 2026 Mid-Year Healthcare Venture Report.

//Contact us

Whether you’re evaluating an opportunity, building a business, raising capital or considering a transaction, or just want to share an idea, let’s have a conversation.

What are you trying to Realize?

Our Address

800 E Leigh Street,
Richmond, Virginia 23219

Submitting you agree with Privacy Policy and Terms of Use.

//Contact us

Whether you’re evaluating an opportunity, building a business, raising capital or considering a transaction, or just want to share an idea, let’s have a conversation.

What are you trying to Realize?

Our Address

800 E Leigh Street,
Richmond, Virginia 23219

Submitting you agree with Privacy Policy and Terms of Use.

//Contact us

Whether you’re evaluating an opportunity, building a business, raising capital or considering a transaction, or just want to share an idea, let’s have a conversation.

What are you trying to Realize?

Our Address

800 E Leigh Street,
Richmond, Virginia 23219

Submitting you agree with Privacy Policy and Terms of Use.

Strategy, business building and investment banking for healthcare.

Contact

800 E Leigh Street,
Richmond, Virginia 23219

Certain securities-related services may be conducted through Sequel Securities LLC, a registered broker-dealer and member FINRA/SIPC. Realize Health Ventures is a separate entity and is not itself a registered broker-dealer.

© 2026 Realize Health Ventures. All rights reserved.

Strategy, business building and investment banking for healthcare.

Contact

800 E Leigh Street,
Richmond, Virginia 23219

Certain securities-related services may be conducted through Sequel Securities LLC, a registered broker-dealer and member FINRA/SIPC. Realize Health Ventures is a separate entity and is not itself a registered broker-dealer.

© 2026 Realize Health Ventures. All rights reserved.

Strategy, business building and investment banking for healthcare.

Contact

800 E Leigh Street,
Richmond, Virginia 23219

Certain securities-related services may be conducted through Sequel Securities LLC, a registered broker-dealer and member FINRA/SIPC. Realize Health Ventures is a separate entity and is not itself a registered broker-dealer.

© 2026 Realize Health Ventures. All rights reserved.